rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21.
|
31371992 |
2019 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21.
|
31371992 |
2019 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21.
|
31371992 |
2019 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After 12 mo of treatment with icotinib, ovarian biopsy showed adenocarcinoma with CDX2(-), TTF-1(+++), PAX8(-), CK-7(+++), CK-20(++), and Ki67(15%+), accompanied with EGFR 19-del mutation and T790M mutation.
|
31363481 |
2019 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We studied the prevalence of T790M mutation among pulmonary adenocarcinoma patients in Lebanese patients based on liquid biopsy testing the circulating tumor DNA (ctDNA).
|
31147859 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or ex</span>on19 delEGFR mutations.
|
30309763 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S.
|
30233215 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We enrolled consecutive patients with operable adenocarcinoma which harbored 19del or L858R to investigate the clinicopathologic characteristics and prognostic outcomes.
|
29026990 |
2018 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We enrolled consecutive patients with operable adenocarcinoma which harbored 19del or L858R to investigate the clinicopathologic characteristics and prognostic outcomes.
|
29026990 |
2018 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S.
|
30233215 |
2018 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or ex</span>on19 delEGFR mutations.
|
30309763 |
2018 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or ex</span>on19 delEGFR mutations.
|
30309763 |
2018 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S.
|
30233215 |
2018 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We enrolled consecutive patients with operable adenocarcinoma which harbored 19del or L858R to investigate the clinicopathologic characteristics and prognostic outcomes.
|
29026990 |
2018 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation.
|
30233215 |
2018 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We report 3 cases of pulmonary adenocarcinoma which did not respond to EGFR-TKI retreatment even with T790M disappearance.
|
30145590 |
2018 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe here on a hitherto unreported mechanism of EGFR TKI resistance synchronously combining squamous-cell carcinoma change and occurrence of the EGFR exon 20 S768I secondary mutation in a 43 year-old woman with stage IV adenocarcinoma harbouring EGFR exon 21 L858R mutation.
|
28024692 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed three major EGFR mutations (L858R in exon 21, E746_A750del in exon 19 and T790M in exon 20) in 80 fresh liquid cytology specimens of adenocarcinoma (ADC) or NSCLC-not otherwise specified (NOS) via the EGFR d-PCR assay and conventional real-time PCR assay using the therascreen® EGFR RGQ PCR kit (Therascreen assay).
|
27922678 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation.
|
28296233 |
2017 |